波生坦治疗肺动脉高压42例临床疗效观察

Therapeutic effect of Bosentan on pulmonary arterial hypertension in 42 patients

目的观察波生坦治疗肺动脉高压临床疗效。方法 42例患者口服波生坦14d前、后观察6min步行距离(6MWD),彩色多普勒超声心动图(UCG)测定肺动脉收缩压(PAP)、动脉血气分析,评估心功能的变化。结果治疗后相关结果均有明显改善,6MWD增加37-139.5(72.3±39.5)m,肺动脉压下降8-37(16.5±8.2)mmHg(1mmHg=0.133kPa),动脉血氧分压(PaO2)上升16-31(22.3±5.8)mmHg;二氧化碳分压(PaCO2)平均下降8-23(14.8±6.7)mmHg,心功能改善提高1级。结论口服波生坦可以显著改善患者耐力及降低肺动脉压。

Objective To observe the therapeutic effect of Bosentan on pulmonary arterial hypertension（PAH） in 42 patients. Methods Sixminute walking distance（6MWD）, pulmonary artery pressure（PAP） on color Doppler echocardiography, arterial blood gas, and cardiac heart function of 42 patients with PAH were observed 14 days before and after the patients were treated with oral Bosentan. Results The 6MWD increased 37-139.5m（72.3 ± 39.5m）, the PAP decreased 8-37mmHg（16.5 ±8.2mmHg）, the PaO2 increased 16-31 mHg（22.3 ± 5.SmmHg）, the PaCO2 decreased 8-23mmHg（14.8 ± 6.7mmHg）, the cardiac function improved 1 grade after the patients were treated with oral Bosentan. Conclusion Oral Bosentan can significantly improve the endurance and decrease the pulmonary artery pressure of patients with PAH.